(2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid

(2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid


    • Product Name (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid
    • Alias (S)-Val-Pro-OMe
    • Einecs 681-391-2
    • Mininmum Order 10mg
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    736998

    Chemical Formula C13H22N2O5
    Molecular Weight 286.324 g/mol
    Iupac Name (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid
    Chirality Has two chiral centers (2S,5S)
    Physical State Predicted Solid (due to its relatively polar functional groups promoting intermolecular interactions)
    Solubility Likely soluble in polar organic solvents like methanol, ethanol, DMSO; less soluble in non - polar solvents like hexane
    Boiling Point Estimated Relatively high boiling point due to hydrogen - bonding and polar interactions, likely above 300°C
    Melting Point Estimated Above 150°C considering its molecular structure and intermolecular forces
    Functional Groups Contains amide, ester, carboxylic acid, and pyrrolidine ring
    Acidity The carboxylic acid group can act as an acid, with an estimated pKa around 3 - 5 for the carboxylic acid moiety

    As an accredited (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 10 grams of (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid in sealed vial.
    Shipping (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid is shipped with strict adherence to chemical transport regulations. It's carefully packaged to prevent damage and ensure safe transit, typically via specialized carriers.
    Storage (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid should be stored in a cool, dry place, away from heat and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Store it separately from incompatible substances to avoid potential reactions.
    Application of (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid

    What Pre-Processing Validations Align with ICH Q7 Section 12.7 for Peptide Intermediate Shipment?

    In the convergent synthesis of voxilaprevir (GS-9857), the fully elaborated C-terminal macrocyclic precursor is assembled via sequential amide couplings, wherein (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid serves as the pre-activated P2–P3 dipeptide acid. This fragment is brought into reaction with the P1–P2 amine hydrochloride in a 1.0:1.03 stoichiometric ratio, mediated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and 1-hydroxybenzotriazole (HOBt) in anhydrous acetonitrile at –5 °C to 0 °C. The downstream macrolactamization step, conducted under pseudodilution conditions (0.005 M) with 2.4 eq. of N,N-diisopropylethylamine, exhibits an epimerization cliff: if the temperature deviates above +8 °C during the 36-hour cyclization, the (2S,5S)/(2R,5S) diastereomeric ratio degrades from ≥99.5:0.5 to 96:4, rendering the batch unrecoverable by seeded crystallization. Regulatory alignment with ICH Q11 requires that the intermediate’s (S,S) configuration be verified via chiral stationary phase HPLC (column: CHIRALPAK IA-3, 250 × 4.6 mm; mobile phase: n-hexane/ethanol/trifluoroacetic acid 80:20:0.1 v/v/v) with retention times for the (2S,5S) enantiomer at 12.7 ± 0.2 min. The final dosage form—voxilaprevir 100 mg film-coated tablet co-formulated with sofosbuvir and velpatasvir—must comply with USP <232>/<233> elemental impurity limits, specifically a cadmium concentration not exceeding 2.0 μg/g. On industrial scale, the intermediate is handled in 316L stainless steel agitated filter-dryers with a nitrogen blanket, and any residual palladium from the catalytic hydrogenolysis step is controlled below 10 ppm.

    Evaluating Diastereoselectivity Cliffs During (2S,5S)-5-Methylpyrrolidine Fragment Activation for Macrocyclic Protease Inhibitors

    When the methoxycarbonyl-valyl-5-methylproline acid is converted to its pentafluorophenyl ester for alternative coupling strategies, the activation chemistry must be confined to a narrow processing window. The conversion proceeds via treatment with pentafluorophenol / 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in ethyl acetate at –10 °C; exceeding –5 °C triggers a base-catalysed diketopiperazine formation pathway that consumes 4–7 % of the activated species within 45 minutes. Protocols aligned with ICH Q7 Section 8.5 (process validation) mandate real-time FTIR monitoring of the ester carbonyl band at 1812 cm⁻¹ to terminate the activation when the diacid impurity index rises above 0.3 area %. The resultant activated ester is reacted in a subsequent displacement step with a macrocycle P1 amino alcohol at a molar ratio of 1.00:0.98 to suppress over-acylation; the crude coupling stream is used directly in a T3P®-mediated macrolactamisation at 50 °C in toluene, yielding a 16-membered ring system. This route delivers the same voxilaprevir API, with the intermediate providing the (2S,5S)-5-methylpyrrolidine-2-carboxylic acid motif as a critical conformational lock. Residual solvent analysis in the isolated intermediate must conform to USP <467> Class 3 limits (acetonitrile ≤ 410 ppm, ethyl acetate ≤ 5000 ppm); the final tablet formulation is tested for dissolution compliance per USP <711>, Apparatus II at 75 rpm.
    Table 1 – Process Windows for Peptide Coupling and Macrolactamization
    Process variableAcceptable rangeCritical failure modeMonitoring method
    Coupling temperature (EDC/HOBt)–5 °C to 0 °CEpimerisation at C-2 (>0.5% D-isomer)Chiral HPLC, CHIRALPAK IA-3
    Macrolactamisation concentration0.004–0.006 MDimerisation/oligomerisation >3%GPC-MALLS, inline refractive index
    Pentafluorophenyl ester activation hold time30 min at –10 °CDiketopiperazine formationReactIR with trendline at 1812 cm⁻¹
    Residual water in intermediate (Karl Fischer)0.15 % w/wHydrolysis of activated esterMetrohm 851 Titrando, oven method

    When Scale-Up Shifts from Batch to Continuous Flow for Amide Bond Formation Under Acid Chloride Activation

    In kilo-lab settings exceeding 50 L, the batch-mode coupling between the P2–P3 acid and the macrocycle amine encounters heat-transport limitations that broaden the residence-time distribution and increase the epimerization risk. To address this, production campaigns at 100 kg scale have adopted a continuous-flow platform: the (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid is first converted to the corresponding acid chloride using 1.05 eq. of thionyl chloride in dichloromethane at 0 °C within a PFA tube reactor (ID 2.0 mm, residence time 45 s), then mixed with a pre-cooled stream of the amine hydrochloride and 2.5 eq. of triethylamine in a second microreactor chip maintained at –15 °C. Under these conditions, the US FDA guidance for continuous manufacturing (ICH Q13) is relevant, and the intermediate quality specification adds a requirement for N,N-dimethylformamide content below 20 ppm (derived from upstream solvent traces) because even 5 ppm residual DMF participates in Vilsmeier-type side reactions during SOCl₂ activation. The isolated crude wax is subjected to a solvent switch into methyl tert-butyl ether and crystallised by controlled cooling (0.2 °C/min) to yield the peptide intermediate in ≥98.5 area % purity. The final drug substance obtained from this intermediate—voxilaprevir—is formulated into fixed-dose combination tablets containing 100 mg voxilaprevir, 400 mg sofosbuvir, and 100 mg velpatasvir, with dissolution acceptance criteria per FDA dissolution database for ANDA filers.A single-point hydrate control failure in the vacuum drying tray dryer can cascade into a coupling yield collapse that remains undetectable by routine loss-on-drying checks. During the production of the title dipeptide acid, a short-term excursion above 60 % relative humidity in the milling suite introduces a monohydrate form that exhibits a broad endotherm centred at 72 °C (DSC) and a shift in the carbonyl stretching region from 1740 cm⁻¹ to 1715 cm⁻¹. When a batch containing 1.3 wt % moisture is deployed in the EDC/HOBt-mediated coupling, the in-situ generation of the O-acylisourea intermediate is competitively quenched; the active ester formation efficiency drops to 61 % of the baseline value, and the downstream macrolactamisation yield falls from 82 ± 2 % to 44 ± 5 %. Consequently, the incoming material specification for the intermediate mandates a Karl Fischer titre of ≤ 0.10 % w/w and a dedicated pre-drying protocol: the powder is held for 12 h at 40 °C under a vacuum of ≤ 10 mbar in a Guedu® agitated vacuum dryer with nitrogen breakthrough. The terminal voxilaprevir tablet batch must also pass ICH Q3D risk assessment for nickel, cobalt, and vanadium, with each element kept below its permitted daily exposure (e.g., Ni ≤ 60 μg/day) based on a maximum daily intake of one 100 mg dose.

    L-Proline-Derived Organocatalysis Bearing a (2S,5S)-5-Methyl Motif in Real-World Asymmetric Aldol Processes

    Beyond its role as an HCV protease inhibitor intermediate, (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid has found industrial utility as a pre-catalyst scaffold in enantioselective carbon–carbon bond formations, particularly for the production of chiral β-hydroxy ketones employed in statin side-chain synthesis. The compound is converted to its free secondary amine form via methyl ester saponification followed by hydrogenolysis, then used at 5 mol % loading in a 300 L jacketed glass-lined reactor to catalyse the aldol reaction between 4-fluorobenzaldehyde and acetone at –20 °C. The optimal catalytic activity requires the addition of 0.5 eq. of benzoic acid as a co-catalyst, which accelerates the formation of the enamine intermediate while suppressing the parasitic oxazolidinone cyclisation that otherwise consumes 8–12 % of the catalyst within 2 h. At full conversion, the (R)-aldol product is obtained in 94 % ee as determined by GC on a Chirasil-DEX CB column; the crude product is directly telescoped into a diastereoselective reduction to generate a key building block for rosuvastatin. From a compliance standpoint, the recovered catalyst stream must be monitored for trace heavy metals introduced by glass-lining wear – an internal specification of Fe ≤ 5 ppm and Ti ≤ 2 ppm is enforced to prevent contamination of the final API. The organocatalyst itself is typically supplied as a lyophilised powder with a chiral purity specification of ≥ 99.0 % ee, tested against ISO 9001:2015 batch release protocols.
    Table 2 – Compliance Matrix for the Title Compound as a GMP Starting Material
    Standard/GuidelineApplicable requirementTest method / limit
    ICH Q7 (GMP for APIs)Sections 7.3, 11.1 – Material receipt and identity testingIR spectrum matching, specific rotation [α]D20 = –78° ± 2° (c=1, MeOH)
    ICH Q3D (Elemental impurities)Class 1, 2A/2B risk assessment for oral dosageICP-MS: As ≤ 1.5 ppm, Pb ≤ 0.5 ppm, Co ≤ 5 ppm
    USP <467> (Residual solvents)Class 2/3 limitsHeadspace GC-FID: acetonitrile ≤ 410 ppm, CH2Cl2 ≤ 600 ppm
    REACH (EC 1907/2006)Registration and supply chain communicationSDS Section 15, tonnage band ≥ 1 tonne/year
    ISO 17025Competence of QC laboratoryChiral HPLC method validation per ICH Q2(R1)
    When a drug master file (DMF) holder integrates the title dipeptide acid into a voxilaprevir ANDA submission, the key regulatory pivot point becomes the designation of the peptide intermediate as the GMP starting material under ICH Q11 Section 5.2. In this framework, the compound is introduced at the point where the final macrolactamisation is executed; its upstream synthesis from (2S,5S)-5-methylpyrrolidine-2-carboxylic acid and N-methoxycarbonyl-L-valine does not require full process validation provided that the impurity profile of the P2–P3 acid is robustly characterised. The typical addition ratio to the P1–P2 amine segment is 1.00:1.02 (molar basis), and any deviation beyond ± 0.03 eq. triggers a re-optimisation of the coupling stoichiometry because the excess unreacted acid co-elutes with the cyclic product in the subsequent silica gel chromatography. The final voxilaprevir tablet manufactured via this route is released against USP monograph (if official) or an in-house validated method for assay (95.0–105.0 %) and related substances (single impurity ≤ 0.5 %, total ≤ 1.5 %).In an analytical reference context, a 50 mg aliquot of the lyophilised intermediate is dissolved in acetonitrile and diluted to a working concentration of 0.1 mg/mL for use as a system suitability solution in LC-HRMS batch release tests. This traceable standard—qualifying under ISO Guide 34—enables concurrent identification of the des-valyl hydrolytic byproduct and the 5-methylpyrrolidine epimer, both of which must be controlled at ≤ 0.10 area % in the final voxilaprevir API. The certificate of analysis for such an analytical batch carries expanded uncertainty (k=2) of ± 0.3 % for purity assignment, determined by mass balance and 1H qNMR with 1,3,5-trimethoxybenzene as internal standard. This usage, while constituting a micro-scale application, drives demand for the compound in strictly GMP-compliant, shippable aliquots that can be directly loaded onto an Acquity UPLC coupled to a Xevo G2-XS QTOF mass spectrometer without further manipulation.
    Free Quote

    Competitive (2S,5S)-1-((Methoxycarbonyl)-L-Valyl)-5-Methylpyrrolidine-2-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    Supplied as a white to off‑white crystalline powder with a molecular formula of C₁₃H₂₂N₂O₅ and a monoisotopic mass of 286.33 g·mol⁻¹, (2S,5S)-1-((methoxycarbonyl)-l-valyl)-5-methylpyrrolidine-2-carboxylic acid functions as a conformationally constrained dipeptide isostere in the synthesis of peptidomimetic pharmacophores. Each batch is packed under argon in Type I borosilicate glass vials with PTFE‑faced septa, and long‑term storage at –20 ± 5 °C is prescribed because the methoxycarbonyl moiety exhibits measurable moisture‑induced degradation at relative humidity above 60 %. Release documentation for every lot includes retention factors from orthogonal HPLC methods, enantiomeric excess determined by chiral stationary‑phase chromatography, and Karl Fischer titrimetry in accordance with ASTM E203. The free acid is fully soluble in dimethylformamide, dimethyl sulfoxide, and warm methanol at concentrations up to 0.25 M, forming clear, colourless to pale‑yellow solutions.

    How Are Batch‑to‑Batch Consistency and Chiral Purity Verified?

    A chiral high‑performance liquid chromatographic method employing an immobilized amylose‑based stationary phase (Chiralpak IA, 250 × 4.6 mm, 5 µm) in polar organic mode—mobile phase 90:10 acetonitrile/methanol with 0.1 % trifluoroacetic acid—separates the (2S,5S) diastereomer from its (2R,5S) epimer and any des-methyl valyl impurity at a retention factor of 2.8. Detection at 210 nm combined with peak‑area integration yields a typical diastereomeric excess exceeding 99.5 %, while purity by complementary reversed‑phase HPLC (C18, gradient from 5 % to 95 % acetonitrile in 0.1 % aqueous formic acid over 20 min) is specified at ≥98.0 %. Specific optical rotation, measured on a digital polarimeter at the sodium D‑line and 20 °C using a 1.0 g·100 mL⁻¹ solution in methanol, falls consistently in the range [α]D²⁰ = –102.5 ± 2.0°. Residual solvents are controlled according to the limits of ICH Q3C Guideline for Class 2 solvents: ethyl acetate is not detected above the quantification threshold of 50 ppm, and dichloromethane remains below 60 ppm when headspace gas chromatography with flame‑ionization detection is applied. Water content, determined by coulometric Karl Fischer titration under ASTM E203, is routinely held below 0.5 wt%. Heavy metals are screened by inductively coupled plasma mass spectrometry after microwave‑assisted acid digestion; the sum of lead, cadmium, arsenic, and mercury does not exceed 10 ppm, conforming to the options outlined in USP <232>. Improper handling—e.g., repeated opening of the vial in ambient air without positive argon pressure—can introduce sufficient moisture to initiate hydrolysis of the methoxycarbonyl carbamate, generating free valyl-proline contaminants that are readily detected as a front‑shoulder peak in the chiral HPLC trace. Coupling (2S,5S)-1-((methoxycarbonyl)-l-valyl)-5-methylpyrrolidine-2-carboxylic acid to a peptide chain immobilized on an aminomethyl‑functionalized resin demands careful selection of activation chemistry because the tertiary amide nitrogen of the 5‑methylproline ring drastically attenuates the electrophilicity of the valine carbonyl. Single‑use aliquots are pre‑activated with 1.2 equivalents of O‑(7‑azabenzotriazol‑1‑yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and 2.0 equivalents of N,N-diisopropylethylamine in anhydrous dimethylformamide at 0.5 M monomer concentration. After a 90‑second activation period at 0 °C, the solution is transferred to the resin and the slurry is agitated at 40 °C for 4 h under nitrogen overlay. When coupling to a sterically encumbered N‑terminal α‑methylvaline residue on a Vydac‑grafied polyethylene glycol support, Kaiser test monitoring shows that 95 % of deprotected amines are capped only after a second coupling cycle of equal duration, raising the overall yield of the desired dimer to 86 % after TFA‑mediated cleavage. By contrast, attempts to substitute carbodiimide‑based activation with ethyl cyanohydroxyiminoacetate (Oxyma) have led to 6–8 % racemization of the valine α‑carbon, as quantified by Marfey’s analysis following total acid hydrolysis; the loss of stereochemical integrity is attributed to the prolonged half‑life of the oxyma ester intermediate in the low‑dielectric environment of the resin‑bound chain. Consequently, HATU‑DIEA is specified on all lot‑specific usage guides, and DIC‑mediated protocols are not recommended. The efficiency of the coupling can be further accelerated by operating at 0.8 M concentration in a mixture of dimethylformamide and N-methyl‑2‑pyrrolidone (1:1 v/v), which reduces solution viscosity and shortens the second coupling to 2.5 h without loss of yield—an adjustment validated across three independent synthetic campaigns on a 100‑mmol scale using a PTFE‑lined jacketed reaction vessel.

    Methoxycarbonyl as an Acid‑Labile Amine Protecting Group with Orthogonal Stability

    The methoxycarbonyl (Moc) substituent on the valine α‑amine undergoes clean cleavage in acidic media, yet it remains intact during catalytic hydrogenolysis, granting orthogonal reactivity when the synthesis demands simultaneous preservation of benzyl ester or carboxybenzyl (Cbz) protecting groups. In a standardized deprotection assay using 50 % (v/v) trifluoroacetic acid in dichloromethane at 25 °C, complete removal of the Moc group is achieved within 30 min, monitored by LC‑MS quantitation of the liberated amine; the rate constant is approximately 0.12 min⁻¹, roughly two‑thirds the value observed for the corresponding tert-butoxycarbonyl (Boc) analog under identical conditions. This slower kinetics provides a practical window for selective Moc removal in the presence of carbamates that are even more acid‑resistant, such as the 2,4‑dimethoxybenzyloxycarbonyl group. The stability of Moc toward hydrogen is leveraged when the molecule is incorporated into sequences that carry Cbz‑protected lysine side chains: exposure to 1 atm hydrogen gas with 10 wt% palladium on carbon in methanol‑acetic acid (9:1 v/v) for 4 h reduces the Cbz group quantitatively while leaving the Moc carbamate unaffected, as confirmed by infrared spectra showing the persistent carbonyl stretch at 1720 cm⁻¹. The 5‑methyl substituent on the pyrrolidine ring contributes an additional layer of acid‑mediated stability at the proline centre; ring‑constrained proline derivatives have been reported to exhibit a reduced tendency for C‑2 epimerization during acidolysis because the methyl group sterically shields the α‑proton from facile abstraction. This property is desirable when the building block is positioned at the C‑terminus of a growing peptide chain, where epimerization risk is normally elevated.

    Structural and Functional Divergence from Alternative Protected Valyl‑Proline Derivatives

    The table below collates key differentiating attributes of (2S,5S)-1-((methoxycarbonyl)-l-valyl)-5-methylpyrrolidine-2-carboxylic acid alongside its most common analogues.
    Compound Protecting Group Cleavage C‑5 Configuration Dominant Ring Pucker HATU‑Mediated Coupling to H‑Leu‑NHMe Epimerization Observed After Acid Deprotection
    (2S,5S)-Moc‑Val‑5‑Me‑Pro‑OH TFA 30 min; stable to H₂/Pd cis‑methyl Cγ‑exo (>85 % at 25 °C in D₂O) 71 % isolated yield after single coupling <0.3 % (²H‑NMR, 500 MHz)
    (2S,5S)-Boc‑Val‑5‑Me‑Pro‑OH TFA 15 min; cleaved by H₂/Pd* cis‑methyl Cγ‑exo 78 % <0.5 %
    (2S,5R)-Moc‑Val‑5‑Me‑Pro‑OH TFA 30 min; stable to H₂/Pd trans‑methyl Cβ‑exo (∼60 %) 43 % <0.3 %
    (2S)-Moc‑Val‑Pro‑OH (no methyl) TFA 30 min; stable to H₂/Pd unsubstituted γ‑turn mixture 82 % 1.1 %
    *Boc removal by hydrogenolysis occurs only under forcing conditions; the value denotes TFA cleavage time under the same assay. The cis‑5‑methyl substitution in the (2S,5S) isomer enforces a highly populated Cγ‑exo puckered conformation, which has been exploited in the design of constrained proline mimetics that pre‑organize the backbone for binding to shallow protease S2 pockets. In contrast, the trans‑methyl diastereomer (2S,5R) adopts a less homogeneous ring geometry and exhibits significantly diminished coupling efficiency to hindered amines, as the upward‑oriented methyl group clashes with the incoming nucleophile during the activated ester collapse. The Boc‑protected variant offers a faster acid deprotection but sacrifices orthogonality with Cbz hydrogenolysis, limiting its utility in hybrid solution‑ and solid‑phase strategies. When the methyl is absent entirely, the ring is more flexible, but the risk of C‑terminal epimerization during acidolytic cleavage increases to approximately 1.1 %, a level that may be unacceptable for active pharmaceutical ingredient intermediate quality standards where diastereomeric purity must exceed 99.5 %. For these reasons, the Moc‑protected (2S,5S) congener is frequently selected in early‑stage structure–activity campaigns where stereochemical fidelity and the ability to carry an orthogonal Cbz‑protected lysine are both mandatory.

    When Stereochemistry at C5 Inverts: Consequences for Macrocyclization Outcome

    A practical distinction emerges when the dipeptide building block is deployed in macrocyclization protocols. Ring‑closing metathesis of an allylglycine‑containing linear heptapeptide that incorporates (2S,5S)-Moc‑Val‑5‑Me‑Pro at the i→i+3 position occurs with a cyclization yield of 52 % under Grubbs second‑generation catalyst (5 mol%) in refluxing dichloromethane, whereas the identical sequence prepared with the (2S,5R) fragment delivers the macrocycle in only 18 % yield. Conformational analysis by ROESY spectroscopy indicates that the cis‑methyl isomer locks the proline residue in a turn‑stabilising geometry that brings the olefinic side chains into a proximity of 3.2 Å, while the trans‑methyl counterpart populates an extended conformation that forces the tethers apart. Given that the syntheses of strained 14‑membered lactams are highly sensitive to pre‑ring closure distance distributions, this conformational pre‑organisation is a decisive factor in selecting the (2S,5S) stereochemistry. Batch records from a kilo‑laboratory campaign employing a cyclic RCM strategy underscore that resin‑bound intermediates built with the (2S,5S) building block exhibited ≤2 % dimeric by‑products, a stark reduction from the 12 % dimer content observed with the trans isomer, thereby obviating a costly preparative HPLC step downstream.